Caseware UK (AP4) 2023.0.135 2023.0.135 2023-11-302023-11-302022-12-01false0No description of principal activity0falsetrueThe members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.false 12293501 2022-12-01 2023-11-30 12293501 2021-12-01 2022-11-30 12293501 2023-11-30 12293501 2022-11-30 12293501 c:Director1 2022-12-01 2023-11-30 12293501 d:CurrentFinancialInstruments 2023-11-30 12293501 d:CurrentFinancialInstruments 2022-11-30 12293501 d:CurrentFinancialInstruments d:WithinOneYear 2023-11-30 12293501 d:CurrentFinancialInstruments d:WithinOneYear 2022-11-30 12293501 d:ShareCapital 2023-11-30 12293501 d:ShareCapital 2022-11-30 12293501 d:RetainedEarningsAccumulatedLosses 2023-11-30 12293501 d:RetainedEarningsAccumulatedLosses 2022-11-30 12293501 c:FRS102 2022-12-01 2023-11-30 12293501 c:AuditExempt-NoAccountantsReport 2022-12-01 2023-11-30 12293501 c:FullAccounts 2022-12-01 2023-11-30 12293501 c:PrivateLimitedCompanyLtd 2022-12-01 2023-11-30 12293501 2 2022-12-01 2023-11-30 12293501 e:PoundSterling 2022-12-01 2023-11-30 iso4217:GBP xbrli:pure

Registered number: 12293501










VITRUVIAN BLOODSTOCK LIMITED








UNAUDITED

FINANCIAL STATEMENTS

INFORMATION FOR FILING WITH THE REGISTRAR

FOR THE YEAR ENDED 30 NOVEMBER 2023

 
VITRUVIAN BLOODSTOCK LIMITED
REGISTERED NUMBER: 12293501

BALANCE SHEET
AS AT 30 NOVEMBER 2023

2023
2022
Note
£
£

  

Current assets
  

Stocks
  
13,690
7,875

Debtors: amounts falling due within one year
 4 
4,382
1,948

Cash at bank and in hand
 5 
-
73

  
18,072
9,896

Creditors: amounts falling due within one year
 6 
(64,318)
(23,182)

Net current liabilities
  
 
 
(46,246)
 
 
(13,286)

Total assets less current liabilities
  
(46,246)
(13,286)

  

Net liabilities
  
(46,246)
(13,286)


Capital and reserves
  

Called up share capital 
  
1
1

Profit and loss account
  
(46,247)
(13,287)

  
(46,246)
(13,286)


The director considers that the Company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the Company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006.

The director acknowledges her responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the statement of comprehensive income in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf on 21 August 2024.




K Priori
Director

The notes on pages 2 to 4 form part of these financial statements.

Page 1

 
VITRUVIAN BLOODSTOCK LIMITED
 

 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 NOVEMBER 2023

1.


General information

Vitruvian Bloodstock Limited is a private company limited by shares incorporated in England & Wales. The registered office is 8 Etherstone Road, London, SW16 2RA.

2.Accounting policies

 
2.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with FRS 102 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland' and the requirements of the Companies Act 2006. The disclosure requirements of Section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The following principal accounting policies have been applied:

 
2.2

Revenue

Revenue is recognised to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured. Revenue is measured as the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. The following criteria must also be met before revenue is recognised:

Sale of goods

Revenue from the sale of goods is recognised when all of the following conditions are satisfied:
the Company has transferred the significant risks and rewards of ownership to the buyer;
the Company retains neither continuing managerial involvement to the degree usually associated with ownership nor effective control over the goods sold;
the amount of revenue can be measured reliably;
it is probable that the Company will receive the consideration due under the transaction; and
the costs incurred or to be incurred in respect of the transaction can be measured reliably.

Rendering of services

Revenue from a contract to provide services is recognised in the period in which the services are provided in accordance with the stage of completion of the contract when all of the following conditions are satisfied:
the amount of revenue can be measured reliably;
it is probable that the Company will receive the consideration due under the contract;
the stage of completion of the contract at the end of the reporting period can be measured reliably; and
the costs incurred and the costs to complete the contract can be measured reliably.

 
2.3

Interest income

Interest income is recognised in profit or loss using the effective interest method.

 
2.4

Borrowing costs

All borrowing costs are recognised in profit or loss in the year in which they are incurred.

Page 2

 
VITRUVIAN BLOODSTOCK LIMITED
 

 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 NOVEMBER 2023

2.Accounting policies (continued)

 
2.5

Taxation

Tax is recognised in profit or loss except that a charge attributable to an item of income and expense recognised as other comprehensive income or to an item recognised directly in equity is also recognised in other comprehensive income or directly in equity respectively.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the balance sheet date in the countries where the Company operates and generates income.

 
2.6

Stocks

Stocks are stated at the lower of cost and net realisable value, being the estimated selling price less costs to complete and sell. Cost is based on the cost of purchase on a first in, first out basis. Work in progress and finished goods include labour and attributable overheads.

At each balance sheet date, stocks are assessed for impairment. If stock is impaired, the carrying amount is reduced to its selling price less costs to complete and sell. The impairment loss is recognised immediately in profit or loss.

 
2.7

Debtors

Short-term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

 
2.8

Cash and cash equivalents

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

 
2.9

Creditors

Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

 
2.10

Financial instruments

The Company has elected to apply the provisions of Section 11 “Basic Financial Instruments” of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the Company's Balance sheet when the Company becomes party to the contractual provisions of the instrument.

Basic financial assets

Basic financial assets, which include trade and other receivables, cash and bank balances, are initially measured at their transaction price including transaction costs and are subsequently carried at their amortised cost using the effective interest method, less any provision for impairment, unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest.

Discounting is omitted where the effect of discounting is immaterial. The Company's cash and cash equivalents, trade and most other receivables due with the operating cycle fall into this category of
Page 3

 
VITRUVIAN BLOODSTOCK LIMITED
 

 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 NOVEMBER 2023

2.Accounting policies (continued)


2.10
Financial instruments (continued)

financial instruments.


3.


Employees




The Company has no employees other than the directors, who did not receive any remuneration (2022 - £NIL).


4.


Debtors

2023
2022
£
£


Trade debtors
3,087
347

Other debtors
1,295
1,601

4,382
1,948



5.


Cash and cash equivalents

2023
2022
£
£

Cash at bank and in hand
-
73

Less: bank overdrafts
(405)
-

(405)
73



6.


Creditors: Amounts falling due within one year

2023
2022
£
£

Bank overdrafts
405
-

Trade creditors
1,589
5,217

Other taxation and social security
-
1,020

Other creditors
59,824
14,445

Accruals and deferred income
2,500
2,500

64,318
23,182



Page 4